Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children’s Oncology Group study AALL0232

Author:

Borowitz Michael J.1,Wood Brent L.2,Devidas Meenakshi3,Loh Mignon L.4,Raetz Elizabeth A.5,Salzer Wanda L.6,Nachman James B.7,Carroll Andrew J.8,Heerema Nyla A.9,Gastier-Foster Julie M.10,Willman Cheryl L.11,Dai Yunfeng3,Winick Naomi J.12,Hunger Stephen P.13,Carroll William L.14,Larsen Eric15

Affiliation:

1. Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD;

2. Department of Laboratory Medicine, University of Washington, Seattle, WA;

3. Department of Biostatistics, Colleges of Medicine and Public Health & Health Professions, University of Florida, Gainesville, FL;

4. Benioff Children’s Hospital and the Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA;

5. Department of Pediatrics, University of Utah, Salt Lake City, UT;

6. US Army Medical Research and Materiel Command, Fort Detrick, MD;

7. Department of Pediatrics, University of Chicago, Chicago, IL;

8. Department of Genetics, University of Alabama at Birmingham, Birmingham, AL;

9. Department of Pathology, The Ohio State University School of Medicine, Columbus, OH;

10. Nationwide Children’s Hospital, Columbus, OH;

11. Cancer Center and Departments of Internal Medicine and Pathology, University of New Mexico, Albuquerque, NM;

12. University of Texas Southwestern Medical Center, Dallas, TX;

13. Department of Pediatrics and the Center for Childhood Cancer Research, Children’s Hospital of Philadelphia, Philadelphia, PA;

14. Department of Pediatrics and The New York University Cancer Institute, New York University Medical Center, New York, NY; and

15. Maine Children’s Cancer Program, Scarborough, ME

Abstract

Key Points MRD measured by flow cytometry is prognostic in childhood B-ALL even with more effective high-dose methotrexate therapy. Intensive therapy in MRD-positive patients altered the timing of relapse but did not overcome the poor prognostic significance of MRD.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3